Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

Inclusion Criteria: * Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy * \>18 years of age * Negative skin test for hypersensitivity to saccharomyces cerevisiae. Exclusion Criteria: * Non-responders to previous interferon treatments * Cirrhosis * HCV treatment within 3 months * Hepatitis B infection * HIV infection